Treatment of intrahepatic cholangiocarcinoma: evidence for the role of percutaneous ablation

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a rare cancer with generally poor prognosis. In this narrative review, we examine the role of thermal ablation and summarize the current literature. Radiofrequency ablation (RFA) and microwave ablation (MWA) are both safe and well-tolerated as a minimally invasive local curative treatment option for patients suffering from primary and secondary liver tumors. Both methods can be used in patients with medical morbidities that would preclude surgery, as well as individuals with anatomical or functional constraints that impede liver resection. In unresectable iCCA, the median OS after conventional percutaneous US- or CT-guided RFA and MWA is between 20 and 39 months and 10 and 28 months, respectively. In recurrent iCCA, percutaneous RFA and MWA achieved a median OS of 21-27 months and 21-31 months, respectively. These data are comparable to long-term outcomes after surgical resection (SR), with the number of nodules and tumor size affecting prognosis. Stereotactic radiofrequency ablation (SRFA) allows for effective treatment of large and multiple iCCA nodules within one session and achieves short- and long-term results in inoperable patients compared with resection. With the addition of SRFA as an alternative treatment option, the proportion of patients who can be treated with curative treatment has significantly increased. In the absence of prospective trials comparing thermal ablation and surgical resection, we recommend a patient-specific decision-making process. Future research to identify technical and clinical prognostic criteria, as well as molecular markers of tumor biology, may help select patients for ablation and subsequent outcomes.

Keywords

Cholangiocellular carcinoma / ablation / radiofrequency ablation / stereotaxy / image fusion / microwave ablation / SRFA / SMWA

References

[1] Beal EW,Moris D.Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr2018;7:270-6 PMCID:PMC6131266

[2] Ma B,Tian Y.Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.BMC Cancer2020;20:318 PMCID:PMC7161164

[3] Akita M,Ajiki T.Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas.Mod Pathol2017;30:986-97

[4] Chapman MH,Hirschfield GM.British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis.Gut2019;68:1356-78 PMCID:PMC6691863

[5] Clements O,Kim JU,Khan SA.Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.J Hepatol2020;72:95-103

[6] European Association for the Study of the Liver. Electronic address: [e-mail], European Association for the Study of the Liver. EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma.J Hepatol2023;79:181-208

[7] Kim YY,Shin H.Clinical staging of mass-forming intrahepatic cholangiocarcinoma: computed tomography versus magnetic resonance imaging.Hepatol Commun2021;5:2009-18 PMCID:PMC8631089

[8] Kim TH,Joo I.Combined hepatocellular-cholangiocarcinoma: changes in the 2019 World Health Organization histological classification system and potential impact on imaging-based diagnosis.Korean J Radiol2020;21:1115-25 PMCID:PMC7458861

[9] Malikowski T,Gleeson FC.Endoscopic ultrasound/fine needle aspiration is effective for lymph node staging in patients with cholangiocarcinoma.Hepatology2020;72:940-8

[10] Fong ZV,Qadan M.The clinical management of cholangiocarcinoma in the united states and europe: a comprehensive and evidence-based comparison of guidelines.Ann Surg Oncol2021;28:2660-74

[11] Cholangiocarcinoma Working Group. Italian clinical practice guidelines on cholangiocarcinoma - part ii: treatment.Dig Liver Dis2020;52:1430-42

[12] Benson AB,Abbott DE.Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Compr Canc Netw2021;19:541-65

[13] Amini N,Spolverato G,Herman JM.Temporal trends in liver-directed therapy of patients with intrahepatic cholangiocarcinoma in the United States: a population-based analysis.J Surg Oncol2014;110:163-70

[14] Mazzaferro V,Roayaie S,Sapisochin G.Liver resection and transplantation for intrahepatic cholangiocarcinoma.J Hepatol2020;72:364-77

[15] Lamarca A,Wasan HS.Advanced intrahepatic cholangiocarcinoma: post Hoc analysis of the ABC-01, -02, and -03 clinical trials.J Natl Cancer Inst2020;112:200-10

[16] Sha M,Xia Q.Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis.Liver Transpl2020;26:1202-3

[17] Sapisochin G,Rubbia-Brandt L.iCCA International ConsortiumLiver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment.Hepatology2016;64:1178-88

[18] Valle JW,Jitlal M.Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.Ann Oncol2014;25:391-8

[19] Oh DY,Lee DW.Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.Lancet Gastroenterol Hepatol2022;7:522-32

[20] Rizzo A.First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: "and yet it moves!.Cancer Treat Res Commun2021;27:100335

[21] Cercek A,Tan BR.Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial.JAMA Oncol2020;6:60-7 PMCID:PMC6824231

[22] Zhou TY,Zhang YL.Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma.J Cancer2020;11:4534-41 PMCID:PMC7255354

[23] Gupta AN,Gabr A.Yttrium-90 radioembolization of unresectable intrahepatic cholangiocarcinoma: long-term follow-up for a 136-patient cohort.Cardiovasc Intervent Radiol2022;45:1117-28

[24] Bargellini I,Pizzi G.Yttrium-90 Radioembolization in unresectable intrahepatic cholangiocarcinoma: results of a multicenter retrospective study.Cardiovasc Intervent Radiol2020;43:1305-14

[25] Jonczyk M,Schnapauff D.Cholangiocarcinoma: CT-guided high-dose rate brachytherapy (CT-HDRBT) for limited (<4 cm) and large (>4 cm) tumors.Anticancer Res2018;38:5843-52

[26] Owen M,Beal EW.Locoregional therapy for intrahepatic cholangiocarcinoma.Cancers2023;15:2384 PMCID:PMC10137284

[27] Franssen S,Jolissaint JS.Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with multifocal intrahepatic cholangiocarcinoma.JAMA Surg2022;157:590-6 PMCID:PMC9096688

[28] Brandi G,Dall'Olio FG.Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience.Int J Hyperthermia2020;37:479-85

[29] Xiang X,Jin Z,Lin H.Radiofrequency ablation vs. surgical resection for small early-stage primary intrahepatic cholangiocarcinoma.Front Oncol2020;10:540662 PMCID:PMC7550467

[30] Bale R,Haidu M.[Stereotactic radiofrequency ablation (SRFA) of intrahepatic cholangiocellular carcinomas: a minimal invasive alternative to liver resection].Wien Med Wochenschr2013;163:128-31

[31] Haidu M,Schullian P.Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study.Cardiovasc Intervent Radiol2012;35:1074-82

[32] Sweeney J,El-Haddad G.Ablation of intrahepatic cholangiocarcinoma.Semin Intervent Radiol2019;36:298-302 PMCID:PMC6823041

[33] Lubner MG,Hinshaw JL.Microwave tumor ablation: mechanism of action, clinical results, and devices.J Vasc Interv Radiol2010;21:S192-203 PMCID:PMC3065977

[34] Lee SM,Shin JH,Chu HH.Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival.Diagn Interv Radiol2020;26:45-52 PMCID:PMC7075581

[35] Shindoh J.Ablative therapies for intrahepatic cholangiocarcinoma.Hepatobiliary Surg Nutr2017;6:2-6 PMCID:PMC5332215

[36] Han K,Kim KW,Shin YM.Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis.J Vasc Interv Radiol2015;26:943-8

[37] Ahmed M,Brace CL.International Working Group on Image-guided Tumor AblationInterventional Oncology Sans Frontières Expert PanelTechnology Assessment Committee of the Society of Interventional RadiologyStandard of Practice Committee of the Cardiovascular and Interventional Radiological Society of EuropeImage-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update.Radiology2014;273:241-60 PMCID:PMC4263618

[38] Slakey DP.Radiofrequency ablation of recurrent cholangiocarcinoma. Am Surg 2002;68:395-7.

[39] Chu HH,Shin YM,Kim PN.Percutaneous radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection: multivariable analysis of factors predicting survival outcomes.AJR Am J Roentgenol2021;217:426-32

[40] Kim JH,Shin YM,Lee SG.Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection.Eur J Radiol2011;80:e221-5

[41] Kim JH,Shin YM,Kim PN.Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma.AJR Am J Roentgenol2011;196:W205-9

[42] Carrafiello G,Cotta E.Radiofrequency ablation of intrahepatic cholangiocarcinoma: preliminary experience.Cardiovasc Intervent Radiol2010;33:835-9

[43] Butros SR,Mueller PR.Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome.Clin Imaging2014;38:490-4

[44] Yu MA,Yu XL.Sonography-guided percutaneous microwave ablation of intrahepatic primary cholangiocarcinoma.Eur J Radiol2011;80:548-52

[45] Wang X,Yu J.Contrast-enhanced ultrasound features predict the prognosis of percutaneous microwave ablation of intrahepatic cholangiocarcinoma.Br J Radiol2022;95:20211379

[46] Ni JY,Zhang TQ,Jiang XY.Predictive value of the albumin-bilirubin grade on long-term outcomes of CT-guided percutaneous microwave ablation in intrahepatic cholangiocarcinoma.Int J Hyperthermia2019;36:328-36

[47] Yang H,Han Z.Assessment of the outcomes of intrahepatic cholangiocarcinoma after ultrasound-guided percutaneous microwave ablation based on albumin-bilirubin grade.Cardiovasc Inter Rad2021;44:261-70

[48] Zhang K,Yu X.Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma.Int J Hyperthermia2018;34:292-7

[49] Giorgio A,Montesarchio L.Intrahepatic cholangiocarcinoma and thermal ablation: long-term results of an italian retrospective multicenter study.J Clin Transl Hepatol2019;7:287-92 PMCID:PMC6943218

[50] Zhang SJ,Wang N.Thermal ablation versus repeated hepatic resection for recurrent intrahepatic cholangiocarcinoma.Ann Surg Oncol2013;20:3596-602

[51] Xu C,Xu W.Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results.Int J Hyperthermia2019;36:350-7

[52] Mulier S,Jamart J,Marchal G.Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors.Ann Surg2005;242:158-71 PMCID:PMC1357720

[53] Laimer G,Jaschke N.Minimal ablative margin (MAM) assessment with image fusion: an independent predictor for local tumor progression in hepatocellular carcinoma after stereotactic radiofrequency ablation.Eur Radiol2020;30:2463-72 PMCID:PMC7160081

[54] Gillams A,Ahmed M.Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology Sans Frontières meeting 2013.Eur Radiol2015;25:3438-54 PMCID:PMC4636513

[55] Lucatelli P,Crocetti L.Percutaneous thermal segmentectomy: proof of concept.Cardiovasc Intervent Radiol2022;45:665-76

[56] Bale R,Stoffner DI.Stereotaxy: breaking the limits of current radiofrequency ablation techniques.Eur J Radiol2010;75:32-6

[57] Ortler M,Bauer R,Trinka E.Flexibility of head positioning and head fixation provided by a novel system for non-invasive maxillary fixation and frameless stereotaxy: technical note.Minim Invasive Neurosurg2009;52:144-8

[58] Freysinger W,Bale R.Three-dimensional navigation in otorhinolaryngological surgery with the viewing wand.Ann Otol Rhinol Laryngol1998;107:953-8

[59] Bale R.Navigated CT-guided interventions.Minim Invasive Ther Allied Technol2007;16:196-204

[60] Bale R,Jaschke W.Stereotaxy and robotics for ablation - toy or tool?.Radiologe2012;52:56-62

[61] Kettenbach J,Toporek G,Kronreif G.A robotic needle-positioning and guidance system for CT-guided puncture: ex vivo results.Minim Invasive Ther Allied Technol2014;23:271-8

[62] Schaible J,Verloh N.Improvement of the primary efficacy of microwave ablation of malignant liver tumors by using a robotic navigation system.Radiol Oncol2020;54:295-300 PMCID:PMC7409605

[63] Scharll Y,Laimer G,Bale R.Puncture accuracy of an optical tracked robotic aiming device-a phantom study.Eur Radiol2022;32:6769-76 PMCID:PMC9474375

[64] Kim-Fuchs C,Lachenmayer A.The role of conventional and stereotactic microwave ablation for intrahepatic cholangiocarcinoma.J Clin Med2021;10:2963 PMCID:PMC8268028

[65] Schullian P,Eberle G,Bale R.Simultaneous Stereotactic radiofrequency ablation of multiple (≥ 4) liver tumors: feasibility, safety, and efficacy.J Vasc Interv Radiol2020;31:943-52

[66] Bale R,Haidu M.Stereotactic radiofrequency ablation.Cardiovasc Inter Rad2011;34:852-6

[67] Schullian P,Putzer D,Laimer G.Safety and efficacy of stereotactic radiofrequency ablation for very large (≥8 cm) primary and metastatic liver tumors.Sci Rep2020;10:1618 PMCID:PMC6994461

[68] Schullian P,Laimer G.Stereotactic radiofrequency ablation of tumors at the hepatic venous confluence.HPB2022;24:1044-54

[69] Schullian P,Putzer D.Stereotactic radiofrequency ablation as first-line treatment of recurrent HCC following hepatic resection.Eur J Surg Oncol2020;46:1503-9

[70] Bale R,Eberle G.Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers.Hepatology2019;70:840-50 PMCID:PMC6766867

[71] Schullian P,Putzer D,Laimer G.Stereotactic radiofrequency ablation of subcardiac hepatocellular carcinoma: a case-control study.Int J Hyperthermia2019;36:876-85

[72] Bale R,Schullian P.Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases.Eur Radiol2012;22:930-7

[73] Schullian P,Laimer G.Stereotactic radiofrequency ablation of breast cancer liver metastases: short- and long-term results with predicting factors for survival.Cardiovasc Intervent Radiol2021;44:1184-93 PMCID:PMC8249280

[74] Putzer D,Bale R.Locoregional ablative treatment of melanoma metastases.Int J Hyperthermia2019;36:59-63

[75] Schullian P,Putzer D.Stereotactic radiofrequency ablation (SRFA) for recurrent colorectal liver metastases after hepatic resection.Eur J Surg Oncol2021;47:866-73

[76] Laimer G,Gottardis M.Stereotactic radiofrequency ablation of an unresectable intrahepatic cholangiocarcinoma (ICC): transforming an aggressive disease into a chronic condition.Cardiovasc Intervent Radiol2020;43:791-6 PMCID:PMC7196948

[77] Braunwarth E,Kummann M.Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma-stereotactic radiofrequency ablation as a valuable addition to hepatic resection.PLoS One2022;17:e0261136 PMCID:PMC8726471

[78] Bale R,Alzaga A.Narrative review of 3D navigated stereotactic liver ablation-do we still need a minimally invasive liver surgeon?.Laparosc Surg2021;5:

[79] de Jong MC,Sotiropoulos GC.Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.J Clin Oncol2011;29:3140-5

[80] Sposito C,Cucchetti A.Survival benefit of adequate lymphadenectomy in patients undergoing liver resection for clinically node-negative intrahepatic cholangiocarcinoma.J Hepatol2023;78:356-63

[81] Koerkamp BG,Polak WG.Surgical resection for intrahepatic cholangiocarcinoma - can we really improve survival by resecting more lymph nodes?.J Hepatol2023;78:235-7

[82] Mosconi C,Javle M.Interventional radiology approaches for intra-hepatic cholangiocarcinoma.Chin Clin Oncol2020;9:8